{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:21:16Z","timestamp":1782886876754,"version":"3.54.5"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHYR"],"published-print":{"date-parts":[[2020,9,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Advances in molecular research techniques have enabled a new frontier in discerning the\nmechanisms responsible for monogenic diseases. In this review, we discuss the current research on\nthe molecular pathways governing blood pressure disorders with a Mendelian inheritance pattern,\neach presenting with a unique pathophysiology. Glucocorticoid Remediable Aldosteronism (GRA)\nand Apparent Mineralocorticoid Excess (AME) are caused by mutations in regulatory enzymes that\ninduce increased production of mineralocorticoids or inhibit degradation of glucocorticoids, respectively.\nGeller syndrome is due to a point mutation in the hormone responsive element of the promotor\nfor the mineralocorticoid receptor, rendering the receptor susceptible to activation by progesterone,\nleading to hypertension during pregnancy. Pseudohypoaldosteronism type II (PHA-II), also\nknown as Gordon\u2019s syndrome or familial hyperkalemic hypertension, is a more variable disorder\ntypically characterized by hypertension, high plasma potassium and metabolic acidosis. Mutations\nin a variety of intracellular enzymes that lead to enhanced sodium reabsorption have been identified.\nIn contrast, hypertension in Liddle\u2019s syndrome, which results from mutations in the Epithelial\nsodium Channel (ENaC), is associated with low plasma potassium and metabolic alkalosis. In Liddle\u2019s\nsyndrome, truncation of one the ENaC protein subunits removes a binding site necessary protein\nfor ubiquitination and degradation, thereby promoting accumulation along the apical membrane\nand enhanced sodium reabsorption. The myriad effects due to mutation in phosphodiesterase 3A\n(PDE3A) lead to severe hypertension underlying sodium-independent autosomal dominant hypertension\nwith brachydactyly. How mutations in PDE3A result in the phenotypic features of this disorder\nare discussed. Understanding the pathologies of these monogenic hypertensive disorders may\nprovide insight into the causes of the more prevalent essential hypertension and new avenues to\nunravel the complexities of blood pressure regulation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573402115666190409115330","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T11:44:27Z","timestamp":1554810267000},"page":"91-107","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical and Molecular Perspectives of Monogenic Hypertension"],"prefix":"10.2174","volume":"16","author":[{"given":"Peter E.","family":"Levanovich","sequence":"first","affiliation":[{"name":"Department of Physiology, Wayne State University School of Medicine and the John D. Dingell VA Medical Center, Detroit, Michigan, MI 48201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Diaczok","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University School of Medicine and the John D. Dingell VA Medical Center, Detroit, Michigan, MI 48201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen F.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Physiology, Wayne State University School of Medicine and the John D. Dingell VA Medical Center, Detroit, Michigan, MI 48201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Hypertension Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/171475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:42:50Z","timestamp":1601044970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/171475\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,9,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573402115666190409115330","relation":{},"ISSN":["1573-4021"],"issn-type":[{"value":"1573-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}